The Lancet ☢️RADICALS-RT follow-up results confirm there is no clear evidence of a benefit of giving radiotherapy soon after surgery for everyone, compared to only giving radiotherapy if the cancer returns.

The results are published in Annals of Oncology👇 9/10
sciencedirect.com/science/articl…

In patients with node-positive breast cancer, axillary recurrence after omission of axillary lymph node dissection was rare with no difference by type of surgery (sentinel lymph node biopsy with dual-tracer mapping vs targeted axillary dissection). ja.ma/3We973M

Progression-free survival and overall survival benefits of adding chemotherapy to gefitinib were sustained at 5 years, confirming earlier results reported at median follow-up of 17 months. ja.ma/3Jw1Ox0

Results of this randomized clinical trial suggest that after induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma, radiotherapy alone was noninferior to chemoradiotherapy in terms of 3-year progression-free survival. ja.ma/3UmwvuH

Postoperative pelvic irradiation combined with concurrent chemotherapy using hypofractionated IMRT with 40 Gy in 16 fractions was safe and well-tolerated in women with cervical cancer, finds nonrandomized controlled trial. ja.ma/3xSOwYS

🚨 FDA grants approval for ADJUVANT ALECTINIB in ALK+ve NSCLC post resection.

——-Brief recap———

👉 Stage IB(4cm and above) - IIIA
👉 Adjuvant ALECTINIB (600mg BD) for 2 years
👉No chemotherapy for patients put on ALECTINIB
👉mDFS NR vs 44mo ( HR < 0.0001 )
👉Around 30%

The OncoAlert 🚨Newsletter is Out
Covering April 5th-12th, 2024

REGISTER at OncoAlert360.com OR oncoalert.m-pages.com/nhMpwe/oncoale…

Discussing:
✅ U.S. FDA approval trastuzumab dx🇺🇸
✅Durvalumab in Small Cell #LungCancer 🫁
✅ALINA 🫁 #NSCLC out on NEJM
✅CD70 CART in

Most viewed in the last 7 days from JAMA Oncology:

Do prostate cancer screening pathways that incorporate MRI and targeted biopsies outperform strategies that rely solely on PSA testing and systematic biopsy?

Presented at #EAU24

ja.ma/4awLFDp

📢 Excited to share our multi-disciplinary, comprehensive review on CSF-based liquid biopsy in brain tumors, which allowed us to outline a potential roadmap to standardizing research done in this realm and optimize the integration of CSF analysis into routine clinical practice.

NRG Oncology/GOG Study 279 | Journal of Clinical Oncology

Impressive 73% complete pathological response and 70% 2y OS in such difficult to treat Vulvar carcinomas with conc chemoRT

Chemo regimen - weekly Gemcitabine (50mg/m2) & CDDP (40mg/m2)

Though it’s a phase II trial, the

💊We're giving the same dose of ICI or TKI to someone who weighs 100 kg and someone who weighs 50 kg.

We say we're in the era of precision medicine, yet we're giving everyone the same dose.

This is a huge contradiction‼️

We must abandon flat doses and find optimal dosing...

TV repair service from ⁦⁦Croma⁩. Pathetic service. They never repaired the TV and today I get a message that repair is completed. ⁦Tata Consumer Products⁩ ⁦Ratan N. Tata⁩

Most cancer drugs granted accelerated approval did not demonstrate benefit in overall survival or quality of life within 5 years of accelerated approval. ja.ma/3J3zZMi #AACR24

🌟 On #WorldHealthDay , let's talk about the power of exercise in cancer prevention and treatment. As an oncologist, I've seen firsthand how physical activity can improve outcomes and quality of life for cancer patients. From reducing the risk of certain cancers to easing

🚨Another Tissue agonistic approval🌟

FDA grants accelerated approval for TDxD in solid tumours with IHC 3+ with metastatic disease and no acceptable alternative treatment options

👉Impressive ORR around 50% for all tumours

Dr Amol Akhade Bijoy Telivala Yakup Ergün

Interesting RCT from Journal of Clinical Oncology evaluating the impact of upfront primary tumor resection on overall survival for patients with unresectable stage IV colon cancer.

It's no surprise to most of us that colectomy does not improve OS.

The study highlights the extreme difficulty in

👑 Docetaxel is still the go to drug for 2nd line mNSCLC without driver mutations post immunotherapy

👉 Docetaxel vs Atezo/Cabozantinib in mNSCLC (2nd line setting)

⭐️No improvement is OS with Atezo/Cabo

⭐️ More AE with Atezo/Cabo

——The wait continues——

Atezolizumab + cabozantinib after disease progression following anti–PD-L1/PD-1 immunotherapy & platinum-containing chemo for metastatic #NSCLC did not improve OS compared with docetaxel, finds CONTACT-01 study.

Article in Journal of Clinical Oncology by Joel W. Neal, MD, PhD, Tom Newsom-Davis & colleagues ⬇️

🏅Systematic review and meta-analysis suggests ➡️
——neo-adjuvant chemo-IMMUNOTHERAPY has better EFS rate than neo-adjuvant chemotherapy for resectable NSCLC even for 🌟PDL-1 LESS THAN 1% Population 🌟 ——-

jamanetwork.com/journals/jamao…

Dr Amol Akhade OncoAlert Non Small Cell Lung

Witnessed the record - breaking total of 277/3, the power-hitting masterclass by Travis Head, Abhishek Sharma, Heinrich Klaasen, and Aiden Markram, and the overall dominance of SRH's batting lineup.

Being able to experience the highest ever scoring T20 game was such a bliss !